Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUB014295 in healthy volunteers
NCT06144684Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Placebo with GUB014295 (2 arms). Primary endpoints: Adverse Events at 127 days, Changes in Vital Signs at 127 days and 1 more. Started Nov 2023; status: completed.
02
Drugs
GUB014295
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06144684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144684.